Hidenori Toyoda
#167,069
Most Influential Person Now
Researcher
Hidenori Toyoda's AcademicInfluence.com Rankings
Hidenori Toyodacomputer-science Degrees
Computer Science
#10127
World Rank
#10622
Historical Rank
Computational Linguistics
#2550
World Rank
#2575
Historical Rank
Machine Learning
#4618
World Rank
#4670
Historical Rank
Artificial Intelligence
#4982
World Rank
#5047
Historical Rank
Download Badge
Computer Science
Hidenori Toyoda's Degrees
- PhD Computer Science University of Tokyo
- Masters Computer Science University of Tokyo
- Bachelors Computer Science University of Tokyo
Similar Degrees You Can Earn
Why Is Hidenori Toyoda Influential?
(Suggest an Edit or Addition)Hidenori Toyoda's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. (2015) (1463)
- Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues (2006) (1198)
- Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis. (2019) (418)
- Association Between Fibrosis Stage and Outcomes of Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis. (2020) (394)
- Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma (1997) (372)
- Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. (2015) (344)
- The Progression of Liver Fibrosis Is Related with Overexpression of the miR-199 and 200 Families (2011) (271)
- Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection. (2018) (268)
- Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open‐label, phase 3 trial (2014) (195)
- Usefulness of albumin–bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma (2016) (183)
- Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients. (2016) (179)
- Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update (2021) (154)
- Deregulation of miR‐92a expression is implicated in hepatocellular carcinoma development (2010) (153)
- Comprehensive miRNA Expression Analysis in Peripheral Blood Can Diagnose Liver Disease (2012) (144)
- Evolution of hypointense hepatocellular nodules observed only in the hepatobiliary phase of gadoxetate disodium-enhanced MRI. (2011) (144)
- Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b–infected Japanese patients with or without cirrhosis (2015) (144)
- FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma (2013) (143)
- Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade (2016) (141)
- Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh Classifications (2017) (133)
- Tumor Markers for Hepatocellular Carcinoma: Simple and Significant Predictors of Outcome in Patients with HCC (2015) (128)
- Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions—Multicenter analysis (2019) (124)
- Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: a propensity score analysis. (2013) (123)
- Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus‐related hepatocellular carcinoma (2007) (123)
- GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis. (2019) (120)
- Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis (2018) (115)
- HBcrAg predicts hepatocellular carcinoma development: An analysis using time-dependent receiver operating characteristics. (2016) (110)
- Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions: Multicenter analysis (2018) (107)
- Transcatheter arterial embolization for massive bleeding from duodenal ulcers not controlled by endoscopic hemostasis. (1995) (104)
- Clinical utility of highly sensitive Lens culinaris agglutinin‐reactive alpha‐fetoprotein in hepatocellular carcinoma patients with alpha‐fetoprotein <20 ng/mL (2011) (103)
- Prognostic significance of simultaneous measurement of three tumor markers in patients with hepatocellular carcinoma. (2006) (103)
- Hepatic Function during Repeated TACE Procedures and Prognosis after Introducing Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Analysis (2017) (102)
- Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection (2017) (100)
- Integration of albumin–bilirubin (ALBI) score into Barcelona Clinic Liver Cancer (BCLC) system for hepatocellular carcinoma (2016) (100)
- Improvement of liver stiffness in patients with hepatitis C virus infection who received direct‐acting antiviral therapy and achieved sustained virological response (2017) (97)
- Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection (2017) (93)
- Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC. (2008) (93)
- Staging hepatocellular carcinoma by a novel scoring system (BALAD score) based on serum markers. (2006) (92)
- B-mode ultrasound with algorithm based on statistical analysis of signals: evaluation of liver fibrosis in patients with chronic hepatitis C. (2009) (90)
- Genome-Wide Association Study Identifies TLL1 Variant Associated With Development of Hepatocellular Carcinoma After Eradication of Hepatitis C Virus Infection. (2017) (89)
- aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. (2020) (87)
- The efficacy of continuous local arterial infusion of 5-fluorouracil and cisplatin through an implanted reservoir for severe advanced hepatocellular carcinoma. (1995) (86)
- Risk factors for long‐term persistence of serum hepatitis B surface antigen following acute hepatitis B virus infection in Japanese adults (2014) (84)
- Clinical Practice Guidelines for Hepatocellular Carcinoma Differ between Japan, United States, and Europe (2015) (84)
- Risk factors of hepatocellular carcinoma development in non‐cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection (2015) (83)
- Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: Multicenter analysis (2018) (78)
- Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis (2016) (78)
- Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response‐Based Approach (2019) (75)
- Estimation of usefulness of N‐butyl‐2‐cyanoacrylate‐lipiodol mixture in transcatheter arterial embolization for urgent control of life‐threatening massive bleeding from gastric or duodenal ulcer (1996) (74)
- Comparison of the Usefulness of Three Staging Systems for Hepatocellular Carcinoma (CLIP, BCLC, and JIS) in Japan (2005) (74)
- The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study (2016) (72)
- Comparison of Hepatocellular Carcinoma miRNA Expression Profiling as Evaluated by Next Generation Sequencing and Microarray (2014) (71)
- Endoscopic management and follow up of Dieulafoy lesion in the upper gastrointestinal tract. (2005) (71)
- Quasispecies nature of hepatitis C virus and response to alpha interferon: significance as a predictor of direct response to interferon. (1997) (69)
- Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B. (2019) (68)
- The expression level of miR-18b in hepatocellular carcinoma is associated with the grade of malignancy and prognosis (2013) (67)
- Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease (2020) (65)
- Non-hypervascular hypointense nodules detected by Gd-EOB-DTPA-enhanced MRI are a risk factor for recurrence of HCC after hepatectomy. (2013) (65)
- High-sensitivity Lens culinaris agglutinin-reactive alpha-fetoprotein assay predicts early detection of hepatocellular carcinoma (2013) (63)
- Efficacy of peginterferon‐α‐2b plus ribavirin in patients aged 65 years and older with chronic hepatitis C (2010) (63)
- Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis. (2019) (63)
- Hepatic microRNA expression is associated with the response to interferon treatment of chronic hepatitis C (2010) (62)
- Relationship between Lens culinaris agglutinin‐reactive α‐fetoprotein and pathologic features of hepatocellular carcinoma (2005) (62)
- Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma (2019) (61)
- Impact of diabetes mellitus on the prognosis of patients with hepatocellular carcinoma (2001) (60)
- Viral eradication reduces all‐cause mortality in patients with chronic hepatitis C virus infection: a propensity score analysis (2016) (58)
- Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion (2017) (57)
- Changes in hepatitis C virus genotype distribution in Japan (2014) (56)
- Utility of real‐time shear wave elastography for assessing liver fibrosis in patients with chronic hepatitis C infection without cirrhosis: Comparison of liver fibrosis indices (2015) (55)
- Impact of surveillance on survival of patients with initial hepatocellular carcinoma: a study from Japan. (2006) (54)
- Prognostic significance of a combination of pre- and post-treatment tumor markers for hepatocellular carcinoma curatively treated with hepatectomy. (2012) (52)
- Retreatment of chronic hepatitis C with interferon. (1994) (52)
- Changes in hepatitis C virus (HCV) antibody status in patients with chronic hepatitis C after eradication of HCV infection by interferon therapy. (2005) (51)
- Double-Contrast Ultrasound: A Novel Surveillance Tool for Hepatocellular Carcinoma (2011) (50)
- Prevalence and clinical implications of occult hepatitis B viral infection in hemophilia patients in Japan (2004) (49)
- Protein and glycomic plasma markers for early detection of adenoma and colon cancer (2016) (49)
- Evaluation for clinical utility of GPC3, measured by a commercially available ELISA kit with Glypican‐3 (GPC3) antibody, as a serological and histological marker for hepatocellular carcinoma (2010) (49)
- Attenuated phosphorylation of heat shock protein 27 correlates with tumor progression in patients with hepatocellular carcinoma. (2005) (48)
- The epidemiology of NAFLD and lean NAFLD in Japan: a meta-analysis with individual and forecasting analysis, 1995–2040 (2021) (47)
- Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan (2017) (47)
- Soluble Axl is an accurate biomarker of cirrhosis and hepatocellular carcinoma development: results from a large scale multicenter analysis (2017) (46)
- Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis (2021) (46)
- Impact of disease stage and aetiology on survival in hepatocellular carcinoma: implications for surveillance (2017) (45)
- A laboratory marker, FIB-4 index, as a predictor for long-term outcomes of hepatocellular carcinoma patients after curative hepatic resection. (2015) (45)
- Utility of Attenuation Coefficient Measurement Using an Ultrasound-Guided Attenuation Parameter for Evaluation of Hepatic Steatosis: Comparison With MRI-Determined Proton Density Fat Fraction. (2019) (45)
- Incidence of hepatocellular carcinoma in hepatitis C carriers with normal alanine aminotransferase levels. (2009) (45)
- Changes in the characteristics and survival rate of hepatocellular carcinoma from 1976 to 2000 (2004) (45)
- Cure With Interferon‐Free Direct‐Acting Antiviral Is Associated With Increased Survival in Patients With Hepatitis C Virus‐Related Hepatocellular Carcinoma From Both East and West (2020) (44)
- Safety and efficacy of lenvatinib in elderly patients with unresectable hepatocellular carcinoma: A multicenter analysis with propensity score matching (2020) (43)
- Phosphorylated Heat Shock Protein 27 Represses Growth of Hepatocellular Carcinoma via Inhibition of Extracellular Signal-regulated Kinase* (2008) (42)
- Predictive value of tumor markers for hepatocarcinogenesis in patients with hepatitis C virus (2011) (41)
- Role of hepatic resection in patients with intermediate‐stage hepatocellular carcinoma: A multicenter study from Japan (2017) (41)
- REAL-B (Real-world Effectiveness from the Asia Pacific Rim Liver Consortium for HBV) Risk Score for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated with Oral Antiviral Therapy. (2020) (41)
- Impact of albumin–bilirubin grade on survival in patients with hepatocellular carcinoma who received sorafenib: An analysis using time‐dependent receiver operating characteristic (2019) (40)
- Neutrophil‐to‐lymphocyte ratio is associated with survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib (2020) (40)
- Incidence of hepatocellular carcinoma in patients with chronic hepatitis B virus infection who have normal alanine aminotransferase values (2010) (40)
- Viral eradication reduces both liver stiffness and steatosis in patients with chronic hepatitis C virus infection who received direct‐acting anti‐viral therapy (2018) (40)
- Prediction of early recurrence of hepatocellular carcinoma after resection using digital pathology images assessed by machine learning (2020) (39)
- The effect of retreatment with interferon‐α on the incidence of hepatocellular carcinoma in patients with chronic hepatitis C (2000) (39)
- Proposed New Sub-Grouping for Intermediate-Stage Hepatocellular Carcinoma Using Albumin-Bilirubin Grade (2016) (38)
- Lenvatinib versus sorafenib in first‐line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis (2021) (38)
- Sofosbuvir–velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals (2018) (38)
- Efficacy and tolerability of an IFN-free regimen with DCV/ASV for elderly patients infected with HCV genotype 1B. (2017) (37)
- Serum WFA+‐M2BP levels as a prognostic factor in patients with early hepatocellular carcinoma undergoing curative resection (2016) (37)
- Cure with Interferon Free DAA is Associated with Increased Survival in Patients with HCV related HCC from both East and West. (2019) (36)
- Geographic distribution and characteristics of genotype A hepatitis B virus infection in acute and chronic hepatitis B patients in Japan (2016) (36)
- Early Relative Change in Hepatic Function with Lenvatinib for Unresectable Hepatocellular Carcinoma (2019) (36)
- Changes in patient backgrounds may increase the incidence of HCC after SVR in the era of IFN‐free therapy for HCV (2016) (35)
- Mutations in the core and NS5A region of hepatitis C virus genotype 1b and correlation with response to pegylated‐interferon‐alpha 2b and ribavirin combination therapy (2011) (35)
- Efficacy of ribavirin plus interferon‐α in patients aged ≥60 years with chronic hepatitis C (2007) (35)
- Association of hepatitis B virus subgenotypes and basal core promoter/precore region variants with the clinical features of patients with acute hepatitis (2008) (35)
- Type 2 diabetes mellitus: A risk factor for progression of liver fibrosis in middle‐aged patients with non‐alcoholic fatty liver disease (2019) (35)
- Biomarker-based prognosis in hepatocellular carcinoma: validation and extension of the BALAD model (2014) (35)
- Comparison of IV contrast-enhanced sonography and histopathology of pancreatic cancer. (2005) (35)
- Post-Progression Treatment Eligibility of Unresectable Hepatocellular Carcinoma Patients Treated with Lenvatinib (2019) (35)
- Chronic hepatitis C: Interferon retreatment of relapsers. A meta‐analysis of individual patient data (1999) (34)
- Role of tumor markers in assessment of tumor progression and prediction of outcomes in patients with hepatocellular carcinoma (2007) (34)
- Significance of tumor vascularity as a predictor of long-term prognosis in patients with small hepatocellular carcinoma treated by percutaneous ethanol injection therapy. (1997) (34)
- Progression of liver fibrosis is associated with non‐liver‐related mortality in patients with nonalcoholic fatty liver disease (2017) (34)
- Association of interleukin 28B and mutations in the core and NS5A region of hepatitis C virus with response to peg‐interferon and ribavirin therapy (2011) (34)
- Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular Carcinoma (2020) (33)
- Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience (2021) (33)
- Liver Care and Surveillance: The Global Impact of the COVID‐19 Pandemic (2020) (33)
- Differences in the impact of prognostic factors for hepatocellular carcinoma over time (2017) (33)
- Impact of a unified CT angiography system on outcome of patients with hepatocellular carcinoma. (2009) (32)
- Novel monitoring of hepatitis B reactivation based on ultra‐high sensitive hepatitis B surface antigen assay (2017) (32)
- Highly Sensitive Lens culinaris Agglutinin-Reactive α-Fetoprotein: A New Tool for the Management of Hepatocellular Carcinoma (2011) (32)
- The chances of hepatic resection curing hepatocellular carcinoma. (2019) (31)
- Comparison of serum hepatitis C virus RNA concentration by branched DNA probe assay with competitive reverse transcription polymerase chain reaction as a predictor of response to interferon‐α therapy in chronic hepatitis C patients (1996) (31)
- The efficacy and safety of glecaprevir plus pibrentasvir in 141 patients with severe renal impairment: a prospective, multicenter study (2019) (31)
- High levels of serum Mac-2-binding protein glycosylation isomer (M2BPGi) predict the development of hepatocellular carcinoma in hepatitis B patients treated with nucleot(s)ide analogues (2018) (29)
- The impact of HCV eradication by direct‐acting antivirals on the transition of precancerous hepatic nodules to HCC: A prospective observational study (2018) (29)
- Hepatitis B virus core‐related antigen levels predict progression to liver cirrhosis in hepatitis B carriers (2018) (28)
- Assessing the impact of COVID-19 on liver cancer management (CERO-19) (2021) (28)
- Clinical characteristics and molecular analysis of hepatitis B virus reactivation in hepatitis B surface antigen-negative patients during or after immunosuppressive or cytotoxic chemotherapy (2016) (28)
- Treatment of Intermediate-Stage Hepatocellular Carcinoma in Japan: Position of Curative Therapies (2019) (28)
- Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium (2019) (27)
- Efficacy and safety of elbasvir/grazoprevir for Japanese patients with genotype 1b chronic hepatitis C complicated by chronic kidney disease, including those undergoing hemodialysis: A post hoc analysis of a multicenter study (2018) (27)
- Difference of HBV Genotype Distribution Between Acute Hepatitis and Chronic Hepatitis in Japan (2006) (27)
- Real-world virological efficacy and safety of elbasvir and grazoprevir in patients with chronic hepatitis C virus genotype 1 infection in Japan (2018) (27)
- Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignancies (2020) (27)
- Suppression by heat shock protein 20 of hepatocellular carcinoma cell proliferation via inhibition of the mitogen‐activated protein kinases and AKT pathways (2011) (27)
- Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting (2020) (27)
- Non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI as a predictor of outcomes for early-stage HCC (2014) (26)
- Transarterial chemoembolization for hepatitis B virus-associated hepatocellular carcinoma: improved survival after concomitant treatment with nucleoside analogues. (2012) (26)
- Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study (2021) (25)
- Predictive Ability of Laboratory Indices for Liver Fibrosis in Patients with Chronic Hepatitis C after the Eradication of Hepatitis C Virus (2015) (25)
- Prevalence of Hepatitis E Virus IgG Antibody in Japanese Patients with Hemophilia (2008) (25)
- Evaluation of pathological features of hepatocellular carcinoma by contrast-enhanced ultrasonography: comparison with pathology on resected specimen. (2006) (25)
- Differences in background characteristics of patients with chronic hepatitis C who achieved sustained virologic response with interferon‐free versus interferon‐based therapy and the risk of developing hepatocellular carcinoma after eradication of hepatitis C virus in Japan (2017) (24)
- Novel method to measure serum levels of des‐gamma‐carboxy prothrombin for hepatocellular carcinoma in patients taking warfarin: A preliminary report (2012) (24)
- Circulating microRNA‐1246 as a possible biomarker for early tumor recurrence of hepatocellular carcinoma (2019) (24)
- Heat shock protein 22 (HSPB8) reduces the migration of hepatocellular carcinoma cells through the suppression of the phosphoinositide 3-kinase (PI3K)/AKT pathway. (2017) (24)
- Heat shock protein 20 (HSPB6) regulates apoptosis in human hepatocellular carcinoma cells: Direct association with Bax. (2014) (24)
- Protein kinase C δ regulates the phosphorylation of heat shock protein 27 in human hepatocellular carcinoma (2007) (23)
- HCC risk post-SVR with DAAs in East Asians: findings from the REAL-C cohort (2020) (23)
- Utility and limitations of noninvasive fibrosis markers for predicting prognosis in biopsy‐proven Japanese non‐alcoholic fatty liver disease patients (2018) (23)
- Treatment and Renal Outcomes Up to 96 Weeks After Tenofovir Alafenamide Switch From Tenofovir Disoproxil Fumarate in Routine Practice (2021) (23)
- EZ-ALBI Score for Predicting Hepatocellular Carcinoma Prognosis (2020) (23)
- Impact of the branched‐chain amino acid to tyrosine ratio and branched‐chain amino acid granule therapy in patients with hepatocellular carcinoma: A propensity score analysis (2015) (23)
- Comparison of hepatitis B virus subgenotypes in patients with acute and chronic hepatitis B and absence of lamivudine‐resistant strains in acute hepatitis B in Japan (2007) (23)
- Dynamic Evaluation of Liver Fibrosis to Assess the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C Who Achieved Sustained Virologic Response. (2019) (23)
- Phosphorylated Heat Shock Protein 20 (HSPB6) Regulates Transforming Growth Factor-α-Induced Migration and Invasion of Hepatocellular Carcinoma Cells (2016) (23)
- Characteristics and prognosis of hepatocellular carcinoma detected in patients with chronic hepatitis C after the eradication of hepatitis C virus: A multicenter study from Japan (2016) (22)
- Real‐world experience of 12‐week direct‐acting antiviral regimen of glecaprevir and pibrentasvir in patients with chronic hepatitis C virus infection (2020) (22)
- Efficacy and safety of ledipasvir/sofosbuvir for genotype 1b chronic hepatitis C patients with moderate renal impairment (2018) (22)
- Analysis of hepatocellular carcinoma tumor growth detected in sustained responders to interferon in patients with chronic hepatitis C 1 (2001) (22)
- Efficacy and safety of ombitasvir/paritaprevir/ritonavir combination therapy for genotype 1b chronic hepatitis C patients complicated with chronic kidney disease (2018) (22)
- The effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients with refractory factors in the real world: a comprehensive analysis of a prospective multicenter study (2020) (21)
- Analysis of efficacy of lenvatinib treatment in highly advanced hepatocellular carcinoma with tumor thrombus in the main trunk of the portal vein or tumor with more than 50% liver occupation: A multicenter analysis (2020) (21)
- Incidence of hepatocellular carcinoma in chronic hepatitis C after interferon therapy. (2002) (21)
- Viral eradication reduces all‐cause mortality, including non–liver‐related disease, in patients with progressive hepatitis C virus‐related fibrosis (2017) (21)
- Surveillance of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease (2020) (21)
- Liver stiffness does not affect ultrasound‐guided attenuation coefficient measurement in the evaluation of hepatic steatosis (2020) (21)
- Post‐treatment levels of α‐fetoprotein predict long‐term hepatocellular carcinoma development after sustained virological response in patients with hepatitis C (2017) (21)
- Treatment of Chronic Hepatitis C with Interferon Alone or Combined with Ribavirin in Japan (2005) (21)
- Evaluation of a new assay for hepatitis C virus genotyping and viral load determination in patients with chronic hepatitis C. (2002) (20)
- Prevalence and clinical characterization of patients with acute hepatitis B induced by lamivudine‐resistant strains (2010) (20)
- Diagnostic accuracy for macroscopic classification of nodular hepatocellular carcinoma: comparison of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging and angiography-assisted computed tomography (2014) (20)
- Impact of hepatitis B virus (HBV) X gene integration in liver tissue on hepatocellular carcinoma development in serologically HBV-negative chronic hepatitis C patients. (2008) (20)
- A better method for assessment of hepatic function in hepatocellular carcinoma patients treated with radiofrequency ablation: Usefulness of albumin–bilirubin grade (2017) (20)
- Presence of multiple genotype-specific antibodies in patients with persistent infection with hepatitis C virus (HCV) of a single genotype: evidence for transient or occult superinfection with HCV of different genotypes (1999) (20)
- Prevalence and characterization of hepatitis C virus genotype 4 in Japanese hepatitis C carriers. (2003) (20)
- Circulating let-7 Levels in Serum Correlate With the Severity of Hepatic Fibrosis in Chronic Hepatitis C (2018) (20)
- Prevalence of hepatitis C virus genotype 1a in Japan and correlation of mutations in the NS5A region and single‐nucleotide polymorphism of interleukin‐28B with the response to combination therapy with pegylated‐interferon‐alpha 2b and ribavirin (2012) (19)
- Changes in Background Liver Function in Patients with Hepatocellular Carcinoma over 30 Years: Comparison of Child-Pugh Classification and Albumin Bilirubin Grade (2020) (19)
- Efficacy of ribavirin plus interferon-alpha in patients aged >or=60 years with chronic hepatitis C. (2007) (19)
- Assay for Hepatitis B Core-related Antigen Identify Patients With High Viral Load: Systematic Review and Meta-analysis of Individual Participant Data. (2020) (19)
- Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC‐B stage patients classified as beyond up to seven criteria – Multicenter analysis (2021) (19)
- Impact of previously cured hepatocellular carcinoma (HCC) on new development of HCC after eradication of hepatitis C infection with non‐interferon‐based treatments (2018) (18)
- Clinical Outcomes in Biopsy-Proven Nonalcoholic Fatty Liver Disease Patients: A Multicenter Registry-Based Cohort Study. (2022) (18)
- Serum hepatitis B core-related antigen predicts hepatocellular carcinoma in hepatitis B e antigen-negative patients (2020) (18)
- Higher hepatic gene expression and serum levels of matrix metalloproteinase-2 are associated with steatohepatitis in non-alcoholic fatty liver diseases (2013) (18)
- Dysregulation of IFN System Can Lead to Poor Response to Pegylated Interferon and Ribavirin Therapy in Chronic Hepatitis C (2011) (18)
- Nutritional Index as Prognostic Indicator in Patients Receiving Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma (2020) (18)
- Efficacy of direct‐acting antiviral treatment in patients with compensated liver cirrhosis: A multicenter study (2018) (18)
- ZEB1 expression is associated with prognosis of intrahepatic cholangiocarcinoma (2015) (18)
- Long-term natural history of liver disease in patients with chronic hepatitis B virus infection: an analysis using the Markov chain model (2018) (17)
- Assessment of tumor hemodynamics in small hepatocellular carcinoma: comparison of Doppler ultrasonography, angiography‐assisted computed tomography, and pathological findings (2004) (17)
- Attenuation imaging based on ultrasound technology for assessment of hepatic steatosis: A comparison with magnetic resonance imaging‐determined proton density fat fraction (2020) (17)
- Prevalence of Low-Level Hepatitis B Viremia in Patients with HBV Surface Antigen-Negative Hepatocellular Carcinoma with and without Hepatitis C Virus Infection in Japan: Analysis by COBAS TaqMan Real-Time PCR (2007) (17)
- Expression levels of heat shock protein 20 decrease in parallel with tumor progression in patients with hepatocellular carcinoma. (2007) (17)
- Effect of the Dose and Duration of Interferon-Alpha Therapy on the Incidence of Hepatocellular Carcinoma in Noncirrhotic Patients with a Nonsustained Response to Interferon for Chronic Hepatitis C (2001) (17)
- Circulating Exosomal miRNA Profiles Predict the Occurrence and Recurrence of Hepatocellular Carcinoma in Patients with Direct-Acting Antiviral-Induced Sustained Viral Response (2019) (17)
- HCV Cure Rates are Reduced in Patients with Active but not Inactive Hepatocellular Carcinoma- A Practice Implication. (2019) (17)
- Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib (2021) (17)
- Trends and Efficacy of Interferon-Free Anti–hepatitis C Virus Therapy in the Region of High Prevalence of Elderly Patients, Cirrhosis, and Hepatocellular Carcinoma: A Real-World, Nationwide, Multicenter Study of 10 688 Patients in Japan (2019) (16)
- Direct Association of Heat Shock Protein 20 (HSPB6) with Phosphoinositide 3-kinase (PI3K) in Human Hepatocellular Carcinoma: Regulation of the PI3K Activity (2013) (16)
- Serum Levels of Alpha Fetoprotein Increased More Than 10 Years Before Detection of Hepatocellular Carcinoma. (2020) (16)
- Ability of Cytokeratin-18 Fragments and FIB-4 Index to Diagnose Overall and Mild Fibrosis Nonalcoholic Steatohepatitis in Japanese Nonalcoholic Fatty Liver Disease Patients (2017) (16)
- Therapeutic efficacy of ramucirumab after lenvatinib for post-progression treatment of unresectable hepatocellular carcinoma (2020) (16)
- Long-term prognosis of patients with chronic hepatitis C who did not receive interferon-based therapy: causes of death and analysis based on the FIB-4 index (2016) (16)
- Mutations in the interferon sensitivity‐determining region of hepatitis C virus genotype 2a correlate with response to pegylated‐interferon‐alpha 2a monotherapy (2009) (15)
- Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysis (2022) (15)
- GALAD Score Detects Early-Stage Hepatocellular Carcinoma in a European Cohort of Chronic Hepatitis B and C Patients (2021) (15)
- New scoring system combining the FIB-4 index and cytokeratin-18 fragments for predicting steatohepatitis and liver fibrosis in patients with nonalcoholic fatty liver disease (2018) (15)
- Evaluation of 8‐week glecaprevir/pibrentasvir treatment in direct‐acting antiviral‐naïve noncirrhotic HCV genotype 1 and 2infected patients in a real‐world setting in Japan (2019) (15)
- Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis (2022) (15)
- A continuous-time hidden Markov model for cancer surveillance using serum biomarkers with application to hepatocellular carcinoma (2019) (15)
- Cholesterol and Lipoprotein Levels as Predictors of Response to Interferon for Hepatitis C (2000) (15)
- Impact of FIB‐4 index on hepatocellular carcinoma incidence during nucleos(t)ide analogue therapy in patients with chronic hepatitis B: An analysis using time‐dependent receiver operating characteristic (2017) (14)
- Utility of Contrast-enhanced Ultrasonography with Perflubutane for Determining Histologic Grade in Hepatocellular Carcinoma. (2015) (14)
- Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child‐Pugh class A or B liver function in real‐world clinical practice (2022) (14)
- Analysis of factors associated with the prognosis of cirrhotic patients who were treated with tolvaptan for hepatic edema (2019) (14)
- Characteristics of elderly hepatitis C virus‐associated hepatocellular carcinoma patients (2013) (13)
- Randomized Phase 3 Trial of Ombitasvir/Paritaprevir/Ritonavir and Ribavirin for Hepatitis C Virus Genotype 2-Infected Japanese Patients (2017) (13)
- Therapeutic efficacy of lenvatinib as third‐line treatment after regorafenib for unresectable hepatocellular carcinoma progression (2021) (13)
- Real-World Clinical Application of 12-Week Sofosbuvir/Velpatasvir Treatment for Decompensated Cirrhotic Patients with Genotype 1 and 2: A Prospective, Multicenter Study (2020) (13)
- Relation between incidence of hepatic carcinogenesis and integration value of alanine aminotransferase in patients with hepatitis C virus infection (2007) (13)
- Impact of modified albumin–bilirubin grade on survival in patients with HCC who received lenvatinib (2021) (13)
- Eight‐week regimen of antiviral combination therapy with peginterferon and ribavirin for patients with chronic hepatitis C with hepatitis C virus genotype 2 and a rapid virological response (2009) (13)
- Proposed a simple score for recommendation of scheduled ultrasonography surveillance for hepatocellular carcinoma after Direct Acting Antivirals: multicenter analysis (2018) (13)
- Correlation of serum zinc levels with pathological and laboratory findings in patients with nonalcoholic fatty liver disease (2020) (13)
- Utility of contrast-enhanced ultrasound with perflubutane for diagnosing the macroscopic type of small nodular hepatocellular carcinomas (2014) (13)
- Influence of Age, Sex, and Degree of Liver Fibrosis on the Association Between Serum Alanine Aminotransferase Levels and Liver Inflammation in Patients with Chronic Hepatitis C (2004) (13)
- Late relapse of hepatitis C virus in patients with sustained virological response after daclatasvir and asunaprevir therapy (2018) (13)
- Changes in highly sensitive alpha-fetoprotein for the prediction of the outcome in patients with hepatocellular carcinoma after hepatectomy (2014) (13)
- Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patients (2021) (12)
- Treatment of Hepatocellular Carcinoma with Child-Pugh C Cirrhosis (2014) (12)
- Effect of daily administration period of natural alpha-interferon in patients with chronic hepatitis C. (1996) (12)
- Heat shock protein 20 (HSPB6) regulates TNF-α-induced intracellular signaling pathway in human hepatocellular carcinoma cells. (2015) (12)
- Natural history of liver‐related disease in patients with chronic hepatitis C virus infection: An analysis using a Markov chain model (2019) (12)
- Global and regional long‐term survival following resection for HCC in the recent decade: A meta‐analysis of 110 studies (2022) (12)
- Utility of the FIB‐4 Index for hepatocarcinogenesis in hepatitis C virus carriers with normal alanine aminotransferase levels (2015) (12)
- Utility of ultrasound-guided attenuation parameter for grading steatosis with reference to MRI-PDFF in a large cohort. (2021) (12)
- Clinical course of liver injury induced by immune checkpoint inhibitors in patients with advanced malignancies (2021) (12)
- Endoscopic papillectomy of minor papillar adenoma associated with pancreas divisum. (2009) (12)
- Long‐term administration of natural interferon‐α in patients with chronic hepatitis C: Relationship to serum RNA concentration, HCV‐RNA genotypes, histological changes and hepatitis C virus (1996) (12)
- Amino Acid Substitutions in the Hepatitis C Virus Core Region Are Associated With Postoperative Recurrence and Survival of Patients With HCV Genotype 1b-Associated Hepatocellular Carcinoma (2011) (12)
- A novel subtype of GB virus C/hepatitis G virus genotype 1 detected uniquely in patients with hemophilia in Japan (2003) (11)
- ALT Levels for Asians With Metabolic Diseases: A Meta‐analysis of 86 Studies With Individual Patient Data Validation (2020) (11)
- Association between HCV amino acid substitutions and outcome of peginterferon and ribavirin combination therapy in HCV genotype 1b and high viral load (2010) (11)
- Long- and short-term outcomes of ERCP for bile duct stones in patients over 80 years old compared to younger patients: a propensity score analysis (2015) (11)
- Oral supplementation with branched‐chain amino acid granules prevents hepatocarcinogenesis in patients with hepatitis C‐related cirrhosis: A propensity score analysis (2014) (11)
- Adverse events as potential predictive factors of activity in advanced hepatocellular carcinoma patients treated with lenvatinib. (2021) (11)
- Characteristics and prognosis of hepatocellular carcinoma detected in sustained responders to interferon therapy for chronic hepatitis C. (2003) (11)
- Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study (2022) (11)
- Impact of genetic polymorphisms near the IL28B gene and amino acid substitutions in the hepatitis C virus core region on interferon sensitivity/resistance in patients with chronic hepatitis C (2011) (10)
- FIB-4 index for assessing the prognosis of hepatocellular carcinoma in patients with Child-Pugh class A liver function (2015) (10)
- Prediction of Hepatocellular Carcinoma by Liver Stiffness Measurements Using Magnetic Resonance Elastography After Eradicating Hepatitis C Virus (2021) (10)
- Characteristics and prognosis of patients with hepatocellular carcinoma after the year 2000 in Japan (2011) (10)
- Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma (2021) (10)
- Liver Fibrosis Indices for Identifying Patients at Low Risk of Developing Hepatocellular Carcinoma after Eradication of HCV (2016) (10)
- Effects of Cirrhosis and Diagnosis Scenario in Metabolic‐Associated Fatty Liver Disease‐Related Hepatocellular Carcinoma (2020) (10)
- Characteristics and Prognosis of Hepatocellular Carcinoma in Japanese Patients Undergoing Dialysis (2017) (10)
- Impact of Branched-Chain Amino Acid Granule Therapy in Patients with Hepatocellular Carcinoma Who Have Normal Albumin Levels and Low Branched-Chain Amino Acid to Tyrosine Ratios (2019) (10)
- Molecular Evolution and Phylodynamics of Acute Hepatitis B Virus in Japan (2016) (10)
- Baseline factors and very early viral response (week 1) for predicting sustained virological response in telaprevir-based triple combination therapy for Japanese genotype 1b chronic hepatitis C patients: a multicenter study (2014) (10)
- Clinical and molecular characteristics of hepatitis A virus infections during the years 1992-2003 in Ogaki, a centrally located city of Japan. (2009) (10)
- Ribavirin and use of clotting factors in patients with hemophilia and chronic hepatitis C. (2005) (10)
- Neutrophil–lymphocyte ratio predicts early outcomes in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: a multicenter analysis (2022) (9)
- What Can Be Done to Solve the Unmet Clinical Need of Hepatocellular Carcinoma Patients following Lenvatinib Failure? (2021) (9)
- Plasma and tumoral glypican‐3 levels are correlated in patients with hepatitis C virus‐related hepatocellular carcinoma (2019) (9)
- Efficacy and safety of ombitasvir/paritaprevir/ritonavir and ribavirin for chronic hepatitis patients infected with genotype 2a in Japan (2019) (9)
- Pharmacotherapy of chronic hepatitis C virus infection – the IDEAL trial: ‘2b or not 2b (= 2a), that is the question’ (2009) (9)
- A nomogram integrating hepatic reserve and tumor characteristics for hepatocellular carcinoma following curative liver resection. (2018) (9)
- Characteristics and prognosis of patients in Japan with viral marker‐negative hepatocellular carcinoma (2008) (9)
- Comparison of the impact of tenofovir alafenamide and entecavir on declines of hepatitis B surface antigen levels. (2020) (9)
- Effect of peginterferon alfa‐2b and ribavirin on hepatocellular carcinoma prevention in older patients with chronic hepatitis C (2015) (9)
- Characteristics and Prognosis of De Novo Hepatocellular Carcinoma After Sustained Virologic Response (2021) (9)
- Significance of early measurement of serum hepatitis C virus RNA in predicting response to interferon therapy in patients with chronic hepatitis C (1997) (9)
- Impact of hepatocellular carcinoma aetiology and liver function on the benefit of surveillance: A novel approach for the adjustment of lead‐time bias (2018) (9)
- Long‐term follow‐up of patients with hepatitis C with a normal alanine aminotransferase (2009) (9)
- Protein kinase C delta regulates the phosphorylation of heat shock protein 27 in human hepatocellular carcinoma. (2007) (9)
- Serum Nutritional Markers as Prognostic Factors for Hepatic and Extrahepatic Carcinogenesis in Japanese Patients with Nonalcoholic Fatty Liver Disease (2020) (8)
- Late-onset colonic occlusion after emergent selective embolization of sigmoid artery with N-butyl cyanoacrylate for life-threatening traumatic bleeding. (2009) (8)
- PNPLA3 and HLA-DQB1 polymorphisms are associated with hepatocellular carcinoma after hepatitis C virus eradication (2020) (8)
- Correlation of serum ribavirin concentration with pretreatment renal function estimates in patients with chronic hepatitis C receiving combination antiviral therapy with peginterferon and ribavirin (2008) (8)
- Outcomes of Sequential Therapy With Tenofovir Alafenamide After Long-term Entecavir. (2021) (8)
- Predictive value of early viral dynamics during peginterferon and ribavirin combination therapy based on genetic polymorphisms near the IL28B gene in patients infected with HCV genotype 1b (2012) (8)
- Impact of COVID‐19 pandemic on surveillance of hepatocellular carcinoma: A study in patients with chronic hepatitis C after sustained virologic response (2020) (8)
- O110 AN INTERNATIONAL COLLABORATIVE STUDY ASSESSING THE ROLE OF AETIOLOGY AND STAGE IN SURVIVAL IN HCC – IMPLICATIONS FOR SCREENING (2014) (8)
- Artificial intelligence (AI) models for the ultrasonographic diagnosis of liver tumors and comparison of diagnostic accuracies between AI and human experts (2022) (8)
- Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study (2022) (8)
- Platelet-lymphocyte ratio predicts survival in patients with hepatocellular carcinoma who receive lenvatinib: an inverse probability weighting analysis. (2020) (8)
- Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis (2022) (8)
- Pretreatment non‐hypervascular hypointense nodules on Gd‐EOB‐DTPA‐enhanced MRI as a predictor of hepatocellular carcinoma development after sustained virologic response in HCV infection (2021) (7)
- Comparison of the efficacy of ribavirin plus peginterferon alfa‐2b for chronic hepatitis C infection in patients with and without coagulation disorders (2013) (7)
- Sequential therapy from entecavir to tenofovir alafenamide versus continuous entecavir monotherapy for patients with chronic hepatitis B (2020) (7)
- Does first‐line treatment have prognostic impact for unresectable HCC?—Atezolizumab plus bevacizumab versus lenvatinib (2022) (7)
- Impact of the introduction of direct‐acting anti‐viral drugs on hepatocarcinogenesis: a prospective serial follow‐up MRI study (2020) (7)
- Mortality of inactive hepatitis B virus carriers in Japan is similar to that of the general population (2021) (7)
- Significance of a reduction in HCV RNA levels at 4 and 12 weeks in patients infected with HCV genotype 1b for the prediction of the outcome of combination therapy with peginterferon and ribavirin (2012) (7)
- Favorable association between genetic polymorphisms near the IL28B gene and hepatic steatosis: direct or indirect? (2012) (7)
- Real-world virological efficacy and safety of daclatasvir/asunaprevir/beclabuvir in patients with chronic hepatitis C virus genotype 1 infection in Japan (2019) (7)
- Is there a survival benefit in interventional radiology for hepatocellular carcinoma in patients with Child–Pugh C liver cirrhosis?: A multicenter study (2016) (7)
- Common Drug Pipelines for the Treatment of Diabetic Nephropathy and Hepatopathy: Can We Kill Two Birds with One Stone? (2020) (7)
- Imaging basis of AFP and WFA+M2BP as indicators of the risk of HCC after SVR. (2017) (6)
- Diagnostic accuracy of two-dimensional shear wave elastography for liver fibrosis: a multicenter prospective study. (2021) (6)
- Validation of the easy‐to‐use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib (2022) (6)
- Comparison of contrast-enhanced harmonic ultrasonography and power Doppler ultrasonography for depicting vascularity of hepatocellular carcinoma identified by angiography-assisted CT. (2003) (6)
- Accurate and rapid identification of feeding arteries with multidetector-row angiography-assisted computed tomography for transarterial chemoembolization for hepatocellular carcinoma (2015) (6)
- Immune-related Liver Injury is a Poor Prognostic Factor in Patients with Nonsmall Cell Lung Cancer Treated with Immune Checkpoint Inhibitors (2021) (6)
- Conserved balance of hepatocyte nuclear DNA content in mononuclear and binuclear hepatocyte populations during the course of chronic viral hepatitis. (2006) (6)
- Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection with and without cirrhosis (2017) (6)
- Impact of Early Lenvatinib Administration on Survival in Patients with Intermediate-Stage Hepatocellular Carcinoma: A Multicenter, Inverse Probability Weighting Analysis (2021) (6)
- Reference change values for lens culinaris agglutinin-reactive α-fetoprotein and des-γ-carboxy prothrombin in patients with chronic hepatitis C (2012) (6)
- CERTAIN-1: efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis (2017) (6)
- Use of hepatitis B virus core‐related antigen to evaluate natural history of chronic hepatitis B (2020) (6)
- Association of interleukin 28B polymorphism and mutations in the NS5A region of hepatitis C virus genotype 2 with interferon responsiveness (2015) (6)
- Long-term prognosis of patients with hepatitis B infection: causes of death and utility of nucleos(t)ide analogue therapy (2015) (6)
- Impact of direct‐acting antiviral agents on liver function in patients with chronic hepatitis C virus infection (2018) (6)
- Time‐course changes in liver functional reserve after successful sofosbuvir/velpatasvir treatment in patients with decompensated cirrhosis (2021) (5)
- Long‐term prognosis with or without nucleot(s)ide analogue therapy in hepatitis B virus–related decompensated cirrhosis (2020) (5)
- Baseline factors and early viral response (week 4) to antiviral therapy with peginterferon and ribavirin for predicting sustained virologic response in patients infected with hepatitis C virus genotype 1: A multicenter study (2013) (5)
- Eradicating Helicobacter pylori in Peptic Ulcer Disease Reduces Medical Costs in the Community (2008) (5)
- Comprehensive analysis of liver and blood miRNA in precancerous conditions (2020) (5)
- Long-term prognosis of liver disease in patients with eradicated chronic hepatitis C virus: an analysis using a Markov chain model. (2020) (5)
- Breaking the Child-Pugh Dogma in Hepatocellular Carcinoma. (2022) (5)
- The emergence of non‐hypervascular hypointense nodules on Gd‐EOB‐DTPA‐enhanced MRI in patients with chronic hepatitis C (2019) (5)
- IMPACT OF TUMOR FACTORS ON THE PROGNOSIS OF PATIENTS WITH ADVANCED CIRRHOSIS (CHILD–PUGH CLASS C) AND HEPATOCELLULAR CARCINOMA (2005) (5)
- Outcome of Hepatocellular Carcinoma Detected During Surveillance: Comparing USA and Japan. (2020) (5)
- Resubclassification and clinical management for Barcelona Clinic Liver Cancer Stage C hepatocellular carcinoma (2021) (5)
- [The pharmacokinetics of the glycyrrhizin and glycyrrhetic acid after intravenous administration of glycyrrhizin for the patients with chronic liver disease caused by type C hepatitis virus]. (1995) (5)
- Improved survival of viral hepatocellular carcinoma but not non‐viral hepatocellular carcinoma from 2000 to 2020: A multi‐centre cohort study of 6007 patients from high‐volume academic centres in Japan (2022) (5)
- A 48‐week telaprevir‐based triple combination therapy improves sustained virological response rate in previous non‐responders to peginterferon and ribavirin with genotype 1b chronic hepatitis C: A multicenter study (2014) (5)
- Chronological change in serum albumin as a prognostic factor in patients with hepatocellular carcinoma treated with lenvatinib: proposal of albumin simplified grading based on the modified albumin–bilirubin score (ALBS grade) (2022) (5)
- Characteristics and course of small hepatocellular carcinomas in patients with hepatitis C virus types 1 and 2 (2001) (5)
- The ALBI score: From liver function in patients with HCC to a general measure of liver function (2022) (5)
- Extra-hepatic feeding arteries of hepatocellular carcinoma: An investigation based on intra-arterial CT aortography images using an angio-MDCT system. (2016) (5)
- Association between hepatic steatosis and hepatic expression of genes involved in innate immunity in patients with chronic hepatitis C. (2013) (5)
- Placement of a sodium hyaluronate solution onto the liver surface as a supportive procedure for radiofrequency ablation of hepatocellular carcinomas located on the liver surface: a preliminary report. (2012) (5)
- Serial changes in serum biomarkers (GALAD model) prior to detection of HCC by ultrasound surveillance; application of statistical process control methodology (2017) (4)
- The course of elderly patients with persistent hepatitis C virus infection without hepatocellular carcinoma (2019) (4)
- Lack of hepatitis C virus reinfection in lifetime of Japanese general population with previous hepatitis C virus (HCV) infection successfully treated with anti-HCV therapy. (2021) (4)
- Comparison of the Prognosis of Decompensated Cirrhosis in Patients with and Without Eradication of Hepatitis C Virus (2021) (4)
- Fully automated rapid quantification of Hepatitis C Virus RNA in human plasma and serum by integrated on-chip RT-qPCR and capillary electrophoresis (2020) (4)
- Clinical features of hemodialysis patients treated for hepatocellular carcinoma: Comparison between resection and radiofrequency ablation (2017) (4)
- Comparison of biochemical safety between PEG-IFN α-2a and PEG-IFN α-2b. (2009) (4)
- ‘YES, NOW YOU ARE FREE FROM CHRONIC HCV INFECTION, BUT . . .’ (2006) (4)
- Progression Rates by Age, Sex, Treatment, and Disease Activity by AASLD and EASL Criteria: Data for Precision Medicine. (2021) (4)
- Mutations of the interferon sensitivity‐determining region (ISDR) correlate with the complexity of hypervariable region (HVR)‐1 in the Japanese variant of hepatitis C virus (HCV) type 1b (2004) (4)
- P554 ASSESSMENT OF PROGNOSIS IN HEPATOCELLULAR CARCINOMA USING A BIOMARKER BASED APPROACH: VALIDATION AND EXTENSION OF THE BALAD MODEL (2014) (4)
- The albumin–bilirubin score as a predictor of outcomes in Japanese patients with PBC: an analysis using time-dependent ROC (2020) (4)
- Poor diagnostic efficacy of noninvasive tests for advanced fibrosis in obese or younger than 60 diabetic NAFLD patients. (2022) (4)
- Comparison of characteristics between patients with GB virus C/hepatitis G virus (GBV‐C/HGV) RNA and those with GBV‐C/HGV E2‐antibody in patients with hemophilia (2000) (4)
- Discrepant imaging findings of portal vein thrombosis with dynamic computed tomography and computed tomography during arterial portography in hepatocellular carcinoma: possible cause leading to inappropriate treatment selection (2017) (4)
- The prognosis of elderly patients with hepatocellular carcinoma: A multi‐center 19‐year experience in Japan (2022) (4)
- Clinical Study of Efficacy of Interferon .ALPHA. for chronic hepatitis C. Evaluation according to Effectiveness and Background. (1994) (4)
- Correction to: Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection (2017) (4)
- Hepatocellular carcinoma recurrence in HCV patients treated with direct-acting antivirals after curative treatment (2019) (3)
- Substitutions in interferon sensitivity‐determining region and hepatocarcinogenesis after hepatitis C virus eradication (2018) (3)
- Influence of liver stiffness heterogeneity on staging fibrosis in patients with nonalcoholic fatty liver disease (2021) (3)
- Cellular Functions of Small Heat Shock Proteins (HSPB) in Hepatocellular Carcinoma. (2021) (3)
- Usefulness of serial FIB-4 score measurement for predicting the risk of hepatocarcinogenesis after hepatitis C virus eradication (2021) (3)
- An early viral response to standard interferon‐alpha identifies resistance to combination therapy with peginterferon and ribavirin in patients infected by HCV genotype 1 (2010) (3)
- Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib (2021) (3)
- Postinterferon α‐fetoprotein elevation and risk of hepatocellular carcinoma development after sustained virological response: Cause or results? (2014) (3)
- Early detection of hepatocellular carcinoma in patients with diabetes mellitus (2019) (3)
- Contrast‐Enhanced Ultrasonographic Assessment of the Response of Ménétrier Disease to Helicobacter pylori Eradication Therapy (2006) (3)
- Emergent transcatheter arterial embolization of ruptured inferior phrenic artery aneurysm with N-butyl cyanoacrylate. (2004) (3)
- Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population. (2022) (3)
- Core I97L mutation in conjunction with P79Q is associated with persistent low HBV DNA and HBs antigen clearance in patients with chronic hepatitis B. (2017) (3)
- BIOCHEMICAL STAGING OF THE CHRONIC HEPATIC LESIONS OF WILSON DISEASE (2014) (3)
- Effect of ribavirin, in combination with interferon in patients with hepatitis C, on the bleeding risk associated with selective serotonin reuptake inhibitors. (2008) (3)
- The expression level of miR-18b in hepatocellular carcinoma is associated with the grade of malignancy and prognosis (2013) (3)
- Long-term prognosis of liver disease in patients with chronic hepatitis B virus infection receiving nucleos(t)ide analogue therapy: an analysis using a Markov chain model. (2019) (3)
- [The study of continuous local arterial-infusion chemotherapy with 5-FU + CDDP for patients with severely advanced HCC--for the elongation of the life-span and the improvement of QOL]. (1993) (3)
- Predictors of Response to 24-Week Telaprevir-Based Triple Therapy for Treatment-Naïve Genotype 1b Chronic Hepatitis C Patients (2014) (3)
- Long-term administration of natural interferon-alpha in patients with chronic hepatitis C: relationship to serum RNA concentration, HCV-RNA genotypes, histological changes and hepatitis C virus. (1996) (3)
- Clinical Predictor of Urinary Protein as Adverse Event Associated with Atezolizumab plus Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma (2022) (3)
- Markedly lower follow-up rate after liver biopsy in patients with non-alcoholic fatty liver diseases than those with viral hepatitis in Japan (2011) (3)
- Impact of Hepatitis B Virus Integration Into Liver Tissue on the Efficacy of Peginterferon and Ribavirin Therapy in Hepatitis B Virus-negative Chronic Hepatitis C Patients (2014) (3)
- GB virus C and mortality from HIV infection. (2002) (3)
- G13 : Ombitasvir/paritaprevir/ritonavir for treatment of HCV genotype 1b in Japanese patients with or without cirrhosis: Results from gift-I (2015) (3)
- [Ruptured aneurysm of a posterior inferior pancreaticoduodenal artery associated with duodenal stenosis after transcatheter arterial embolization]. (2011) (2)
- Simultaneous multicentric occurrence of early hepatocellular carcinoma in a patient with persistent alpha‐fetoprotein elevation (2007) (2)
- Pegylated interferon monotherapy in patients with chronic hepatitis C with low viremia and its relationship to mutations in the NS5A region and the single nucleotide polymorphism of interleukin‐28B (2013) (2)
- FGF3/FGF4 Amplification and Multiple Lung Metastases in Responders to Sorafenib in Hepatocellular Carcinoma (2013) (2)
- Utility of serological tumor biomarkers for surveillance of hepatocellular carcinoma in patients undergoing dialysis. (2020) (2)
- Identification of CT Values That Could Be Predictive of Necrosis (N-CTav) in Hepatocellular Carcinoma after Lenvatinib Treatment (2022) (2)
- Erratum to: Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis (2016) (2)
- Utility of FIB4-T as a Prognostic Factor for Hepatocellular Carcinoma (2019) (2)
- Development and validation of a modified albumin–bilirubin grade and α-fetoprotein score (mALF score) for hepatocellular carcinoma patients receiving atezolizumab and bevacizumab (2022) (2)
- Factors associated with sustained virological response in 24‐week telaprevir‐based triple therapy for chronic hepatitis C genotype 1b patients with the IL28B minor genotype (2015) (2)
- Incidence of hepatocellular carcinoma and response to interferon therapy in HCV‐infected patients: effect of factors associated with the therapeutic response and incidence of HCC (2012) (2)
- Influence of renal dysfunction on dose reduction and virologic efficacy of regimens combining ribavirin and all‐oral direct acting antivirals in patients with chronic hepatitis C virus infection (2019) (2)
- Adherence to regular surveillance visits for hepatocellular carcinoma in patients with chronic hepatitis C virus infection who achieved sustained virologic response (2022) (2)
- Genome-Wide Association Study Identi fi es TLL 1 Variant Associated With Development of Hepatocellular Carcinoma After Eradication of Hepatitis C Virus Infection (2017) (2)
- Hepatocellular Carcinoma Risk Assessment for Patients With Advanced Fibrosis After Eradication of Hepatitis C Virus (2021) (2)
- Clinical Profiles of Asians with NAFLD: A Systematic Review and Meta-Analysis (2021) (2)
- Usefulness of ALBI grade in prediction of outcomes in patients with hepatitis B related hepatocellular carcinoma (2017) (2)
- Comparative efficacy and safety of atezolizumab and bevacizumab between hepatocellular carcinoma patients with viral and non‐viral infection: A Japanese multicenter observational study (2022) (2)
- Differences in viral kinetics between genotypes 1 and 2 of hepatitis C virus after single administration of standard interferon‐alpha (2009) (2)
- Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study. (2022) (2)
- Effectiveness of entecavir vs tenofovir disoproxil fumarate for functional cure of chronic hepatitis B in an international cohort (2022) (2)
- Factors linked to hepatocellular carcinoma development beyond 10 years after viral eradication in patients with hepatitis C virus (2022) (2)
- Clinical outcomes of antithrombin III‐based therapy for patients with portal vein thrombosis: A retrospective, multicenter study (2022) (2)
- Comparison of liver disease state progression in patients with eradication of versus persistent infection with hepatitis C virus: Markov chain analysis (2020) (2)
- Congestion of Superior Mesenteric Veins and Small Bowel Mucosal Injury After Endoscopic Treatment of Esophageal Varices in Patients with Portal Hypertension (2001) (2)
- Assessment of liver dysfunction in hepatocellular carcinoma (HCC): An international collaborative study. (2014) (2)
- A novel noninvasive formula for predicting cirrhosis in patients with chronic hepatitis C (2021) (2)
- Comparison of biochemical safety between PEG-IFN alpha-2a and PEG-IFN alpha-2b. (2009) (2)
- Clinical Significance of Two Real-Time PCR Assays for Chronic Hepatitis C Patients Receiving Protease Inhibitor-Based Therapy (2017) (2)
- Prognostic impact of serum alpha-fetoprotein in patients with hepatocellular carcinoma: an international collaborative study (2017) (2)
- Soluble Axl identifies patients at higher risk for hepatocellular carcinoma development: results from a large scale multicenter analysis (2017) (2)
- Direct‐acting antiviral therapy for chronic hepatitis C virus genotype 4 infection: Exploring new regimens (2019) (2)
- Utility of combined gray‐scale and perflubutane contrast‐enhanced ultrasound for diagnosing early hepatocellular carcinomas: Comparison of well differentiated and distinctly nodular types (2016) (2)
- Characteristics and Outcomes of HCV Genotype-1-Infected Patients Treated with Peginterferon and Ribavirin Combination Therapy with Discordant HCV Responses 4 and 12 Weeks after Starting Therapy (2014) (2)
- Mac‐2‐binding protein glycan isomer predicts all malignancies after sustained virological response in chronic hepatitis C (2022) (2)
- Abnormal fucosylation of alpha‐fetoprotein in patients with nonalcoholic steatohepatitis (2021) (2)
- Sustained virologic response (SVR) to direct-acting antiviral (DAA) therapy in patients with chronic hepatitis C virus (HCV) infection and hepatocellular carcinoma (HCC): a systematic review and meta-analysis (2018) (1)
- Efficacy and safety of elbasvir and grazoprevir for chronic hepatitis C patients with chronic kidney disease (2017) (1)
- [The clinical evaluation of hepatic arterial infusion chemotherapy in patients with liver metastases from colorectal cancer employing an implanted port system]. (1996) (1)
- Significance of day‐1 viral response of hepatitis C virus in patients with chronic hepatitis C receiving direct‐acting antiviral therapy (2018) (1)
- Safety, feasibility, and comfort of hepatic angiography and transarterial intervention with radial access for hepatocellular carcinoma (2021) (1)
- Liver Stiffness Measurements by 2D Shear-Wave Elastography: Effect of Steatosis on Fibrosis Evaluation. (2022) (1)
- Acute pancreatitis as a complication of choledocholithiasis (2005) (1)
- Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab. (2022) (1)
- Serial changes in FIB‐4 score and hepatocarcinogenesis in hepatitis B patients treated with or without nucleot(s)ide analogue therapy (2020) (1)
- IDDF2018-ABS-0110 Efficacy and safety of SOFOSBUVIR/VELPATASVIR plus RIBAVIRIN for 12 or 24 weeks in genotype 1 or 2 HCV-INFECTED japanese patients with prior treatment failure to daa-based regimens (2018) (1)
- Factors Associated with Hepatitis B Surface Antigen Kinetics and Responses in Pegylated Interferon Alpha-2a Monotherapy for Patients with Chronic Hepatitis B (2021) (1)
- International multicenter validation of GES score for HCC risk stratification in chronic hepatitis C patients (2021) (1)
- Marked heterogeneity in the diagnosis of compensated cirrhosis of patients with chronic HCV infection in a real-word setting: a large, multicenter study from Japan. (2020) (1)
- Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis? (2023) (1)
- A multicenter, retrospective, cohort study shows platelet counts predict HCC development in patients with NAFLD. (2023) (1)
- [Analysis of methods of administration on local arterial infusion chemotherapy for severe advanced hepatocellular carcinoma]. (1994) (1)
- Transient reappearance of serum hepatitis C virus RNA observed by real-time PCR during antiviral therapy with peginterferon and ribavirin in patients with HCV genotype 1b. (2010) (1)
- EFFICACY OF N-BUTYL-2-CYANOACRYLATE (HISTOACRYL) ON TRANSCATHETER ARTERIAL EMBOLIZATION FOR BLEEDING FROM GASTRODUODENAL ULCERS (1994) (1)
- Development and multicenter validation of FIB‐6: A novel, machine learning, simple bedside score to rule out liver cirrhosis and compensated advanced chronic liver disease in patients with chronic hepatitis C (2021) (1)
- Nutritional Status Is Associated with Prognosis in Patients with Advanced Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab (2022) (1)
- Outcome in partial early virologic responders to combination therapy with peginterferon and ribavirin in patients infected with hepatitis C virus genotype 1b (2011) (1)
- C-reactive protein to albumin ratio predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib (2022) (1)
- Simple method with tumor markers for predicting prognosis following transcatheter arterial chemo-embolization for switching to next therapy in intermediate hepatocellular carcinoma: multi-center analysis (2017) (1)
- Impact of switching to tenofovir alafenamide fumarate in patients with entecavir-treated chronic hepatitis B (2021) (1)
- [Clinical evaluation of a recurrent mode after treatment in patients with small hepatocellular carcinoma]. (1995) (1)
- A Reappraisal of the Diagnostic Performance of B-Mode Ultrasonography for Mild Liver Steatosis (2022) (1)
- 328: REAL-WORLD TREATMENT OUTCOME WITH PROTEASE INHIBITOR (PI) VS NON-PI DIRECT ACTING ANTIVIRALS (DAAS) IN DECOMPENSATED HCV CIRRHOSIS: A REAL-C STUDY (2022) (1)
- Glasgow prognostic score predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib: a multicenter analysis (2022) (1)
- Survival analysis of Sorafenib in patients with advanced hepatocellular carcinoma (2010) (1)
- No increased risk of hepatocellular carcinoma after eradication of hepatitis C virus by direct-acting antivirals, compared with interferon-based therapy. (2022) (1)
- Relationship between COVID-19 and liver diseases: the role of hepatologists in clinical practice (2020) (1)
- Evaluation of the aMAP score for hepatocellular carcinoma surveillance: a realistic opportunity to risk stratify (2022) (1)
- Prospective study of a high-intensity interferon-alpha regimen for chronic hepatitis C virus genotype 1b infection. (2002) (1)
- A case of the giant liver cell adenoma. Review of Japanese literatures. (1995) (1)
- New prognostic system based on inflammation and liver function predicts prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: A validation study (2022) (1)
- Antiviral combination therapy with peginterferon and ribavirin does not induce a therapeutically resistant mutation in the HCV core region regardless of genetic polymorphism near the IL28B gene (2011) (1)
- Long‐term outcomes of viral eradication in patients with hepatitis C virus infection and mild hepatic fibrosis (2021) (1)
- Effect of Coinfection With Hepatitis G Virus on HIV Disease Progression in Hemophilic Men (1998) (1)
- Hepatic microRNA expression is associated with the responseto interferon treatment of chronic hepatitis C . Author ( s ) (2017) (0)
- Association between HCV Amino Acid Substitutions and Outcome of Peginterferon and Ribavirin Combination Therapy in HCV Genotype 1b and High Viral Load: Amino acid substitutions of HCV genotype 1b (2009) (0)
- New scoring system using MRI with AST for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis (2022) (0)
- Diversity of Nucleotide Sequences in Hypervariable Region 1 of Hepatitis C Virus in Japanese Patients with Chronic Hepatitis C of Unknown Mode of Transmission (1999) (0)
- Which Therapeutic Method Should be Selected in Non-Viral Hepatitis and Early Hepatocellular Carcinoma: Resection or Ablation? Multi-Center Analysis Using with Propensity Score Matching (2017) (0)
- therapy virus and human immunodeficiency virus: influence of antiretroviral Immunologic dynamics in hemophiliac patients infected with hepatitis C (2013) (0)
- Sofosbuvir/velpatasvir and glecaprevir/pibrentasvir: how should we choose among these two latest and probably the last regimens? (2022) (0)
- The impact of HCV eradication by IFN-free regimens on the transition of precancerous hepatic nodules to HCC: a prospective observational study (2018) (0)
- [Clinical study of continuous local arterial-infusion chemotherapy for severely advanced hepatocellular carcinoma (HCC) using reservoir]. (1993) (0)
- SAT-181-Efficacy and safety of glecaprevir/pibrentasvir in patients with severe renal impairment in Japan: A prospective, multicenter study (KTK 49 Liver Study Group) (2019) (0)
- Incidence and risk factors of esophagogastric varices bleeding in cirrhotic patients with advanced hepatocellular carcinoma treated with lenvatinib (2023) (0)
- Reply to: "HBV markers for HCC prediction: Three heads are better than two?" (2017) (0)
- PS-136-Can lenvatinib meet clinical needs of patients with unresectable hepatocellular carcinoma? Multicenter analysis (2019) (0)
- Re: García-Samaniego et al.—Hepatocellular carcinoma in patients with HCV-HIV coinfection (2001) (0)
- Association of PPI and antibiotics with the clinical outcomes of HCC patients receiving atezolizumab and bevacizumab: A multicenter analysis. (2023) (0)
- Lower incidence of hepatocellular carcinoma in patients with transient virologic response to peginterferon and ribavirin combination therapy: is it really the effect of the therapy? (2013) (0)
- Correlation between the complex of small heat shock proteins (HSPBs) and the progression in patients with hepatocellular carcinoma. (2022) (0)
- [Trial of self-management of outpatients with implanted reservoir for arterial infusion of anticancer drugs]. (1994) (0)
- Front & Back Matter (2012) (0)
- [Case of small bowel angioectasia in which the resection site was angiographically detected using intraoperative dye infusion]. (2014) (0)
- Identification of CT Attenuation Values that Could be Predictive of Necrosis (N-CTav) in Hepatocellular Carcinoma Tumors after Lenvatinib Treatment and the Association between the N-CTav Occupancy Rate in the Tumor and Maintenance of Complete Response with Lenvatinib Treatment (2022) (0)
- M1783 Effect of Pegylated-IFN-Alpha-2a Monotherapy in Patients with Chronic Hepatitis C Infected with Low Pretreatment Viremia and Relationship to Amino Acid Substitutions in NS5A Region (2009) (0)
- Running head : Liver stiffness in HCV patients with SVR (2017) (0)
- Liver Damage Related with Hepatitis C and Human Immune Deficiency Coinfection (2003) (0)
- A case of intraductal papillary neoplasm of the bile duct observed by follow-up ultrasonic examination (2019) (0)
- Title Expression levels of heat shock protein 20 decrease in parallel with tumor progression in patients with hepatocellular carcinoma (2017) (0)
- Real-World Virological Efficacy and Safety of Ledipasvir and Sofosbuvir in Patients with Chronic Hepatitis C Virus Genotype 2 Infection: A Multicenter Study (2020) (0)
- The Impact of Cirrhosis and History of Hepatocellular Carcinoma on All-Cause Mortality After Eradication of Hepatitis C Virus in Patients With Chronic Hepatitis C (2022) (0)
- Misunderstanding of hepatitis C virus (HCV) infection status by non-specialized medical doctors in patients who achieved sustained virologic response to anti-HCV therapy. (2022) (0)
- Title Hepatic microRNA expression is associated with the responseto interferon treatment of chronic hepatitis C (2019) (0)
- Su1470 Curative Treatments of Hemodialysis Patients With Hepatocellular Carcinoma: Comparison Between Resection and Radiofrequency Ablation (2016) (0)
- Validation of the utility of Agile scores to identify advanced fibrosis and cirrhosis in Japanese patients with nonalcoholic fatty liver disease. (2023) (0)
- [Hepatic arterial infusion chemotherapy for colorectal liver metastases]. (2004) (0)
- Low surveillance receipt in cirrhotic patients with cured HCV: Where are the barriers? (2023) (0)
- Predictive value of cytokeratin-18 fragment levels for diagnosing steatohepatitis in patients with nonalcoholic fatty liver disease (2021) (0)
- Hepatitis C virus genotypes in hemophiliacs with chronic hepatitis C (2002) (0)
- Letter: rising incidence and poor survival in patients with non‐viral HCC – better HCC surveillance and treatment for alcohol‐associated and non‐alcohol fatty liver diseases are needed. Authors' reply (2023) (0)
- Serum markers of liver fibrosis (2018) (0)
- Diagnostic accuracy of enhanced liver fibrosis test for nonalcoholic steatohepatitis‐related fibrosis: Multicenter study (2022) (0)
- Time of initiation of therapy for early hepatocellular carcinoma (2011) (0)
- Analysis of factors associated with the prognosis of cirrhotic patients who were treated with V2-receptor antagonist for hepatic edema (2020) (0)
- Trends of hepatitis B virus genotype distribution in chronic hepatitis B patients in Japan (2022) (0)
- Simple scoring index for early detection of non-B, non-C hepatocellular carcinoma in patients with diabetes mellitus (2019) (0)
- Early changes in circulating FGF19 and ANG-2 levels as a possible predictive biomarker for lenvatinib therapy in hepatocellular carcinoma (2020) (0)
- 510 PROGRESSION OF CHRONIC HEPATITIS B TO CIRRHOSIS AND HEPATOCELLULAR CARCINOMA BY AGE, SEX, DISEASE ACTIVITY, AND TREATMENT STATUS USING AASLD CRITERIA (2021) (0)
- Intra-individual Comparisons of the Ultrasound-Guided Attenuation Parameter and the Magnetic Resonance Imaging-Based Proton Density Fat Fraction Using Bias and Precision Statistics. (2022) (0)
- Contents Vol. 35, 2017 (2017) (0)
- Combined ultrasound and magnetic resonance elastography predict hepatocellular carcinoma after hepatitis C virus eradication (2022) (0)
- Long‐term persistence of hepatocarcinogenic potential of a non‐hypervascular hypointense nodule on EOB‐MRI after the eradication of hepatitis C virus (2021) (0)
- Rapid quantification assay of hepatitis B virus DNA in human serum and plasma by Fully Automated Genetic Analyzer μTASWako g1 (2023) (0)
- Comment on: Hepatocellular carcinoma in patients with HCV-HIV coinfection. Authors' reply (2001) (0)
- Tu1310: NON-INVASIVE TESTS (NITS) FOR PREDICTING HEPATOCELLULAR CARCINOMA IN NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) PATIENTS WITHOUT CIRRHOSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF INDIVIDUAL PATIENT DATA AND AGGREGATE DATA (2022) (0)
- Excess mortality risk among hepatitis C patients after being “cured” in the interferon-free era: results from three population-based cohorts (2022) (0)
- Long-Term Impact of Response to Interferon-Based Therapy in Patients with Chronic Hepatitis C Virus in Relation to Liver Function, Survival and Cause of Death (2016) (0)
- Reply to: Comment on: ‘Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade' (2016) (0)
- Anti-HCV Agent, Ribavirin, Decreases Events of Bleeding in Hemophilia Patients, Possibly by Elevating the Clotting Activity of Factor VII. (2005) (0)
- 2000: Quantification of liver fibrosis in patients with chronic hepatitis C using a new analysis software (2006) (0)
- Efficacy and Safety of Glecaprevir/Pibrentasvir Combination Therapy in Genotype 1b Chronic Hepatitis C Patients with and without Cirrhosis Undergoing Hemodialysis (2018) (0)
- Shorter pruritus period and milder disease stage are associated with response to nalfurafine hydrochloride in patients with chronic liver disease (2022) (0)
- Transnasal Endoscope Locked in a Bent Position Causing Difficult Withdrawal (2014) (0)
- Sa1396: ANTIVIRAL THERAPY IMPROVES SURVIVAL IN VIRAL-ASSOCIATED HEPATOCELLULAR CARCINOMA AFTER LIVER RESECTION BUT IS SEVERELY UNDERUTILIZED (2022) (0)
- Impact of HBV Infection on Outcomes of Direct-Acting Antiviral Therapy of Chronic Hepatitis C (2017) (0)
- Response to Gelderblom et al. (2010) (0)
- Comparison of Contrast-enhanced Ultrasonography Images by Sonazoid® and Levovist® in Hepatic Tumors (2007) (0)
- Risk factors for portopulmonary hypertension in patients with cirrhosis: a prospective, multicenter study (2022) (0)
- Week 4 viral response to peginterferon and ribavirin: how should it be used in combination with a baseline predictive factor? (2012) (0)
- Correction to: Development and validation of a modified albumin–bilirubin grade and α-fetoprotein score (mALF score) for hepatocellular carcinoma patients receiving atezolizumab and bevacizumab (2022) (0)
- Multicenter, retrospective, cohort study shows platelet counts predict hepatocellular carcinoma development in patients with nonalcoholic fatty liver disease (2023) (0)
- A Reappraisal of the Diagnostic Performance of Ultrasonography for Mild Fatty Liver Disease (2022) (0)
- Impact of curative HCC history on the development of HCC after the eradication of HCV by DAA therapy in patients with HCV infection (2018) (0)
- 595 ASSOCIATION BETWEEN AMINO-ACID SEQUENCES OF HEPATITIS C VIRUS (HCV) CORE, E1, AND NS5A REGIONS AND OUTCOME OF PEGINTERFERON/RIBABIRIN THERAPY IN HCV GENOTYPE 1B (2009) (0)
- Age‐dependent effects of diabetes and obesity on liver‐related events in non‐alcoholic fatty liver disease: Subanalysis of CLIONE in Asia (2022) (0)
- Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients. (2023) (0)
- Serum osteopontin predicts the response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma. (2023) (0)
- Subject Index Vol. 81, Suppl. 1, 2011 (2011) (0)
- Editorial: non‐viral hepatocellular carcinoma surveillance—an increasingly severe public health issue. Authors' reply (2022) (0)
- 295 - Sustained Virologic Response (SVR) to Direct-Acting Antiviral (DAA) Therapy in Patients with Hepatitis C Virus (HCV) Infection and Hepatocellular Carcinoma (HCC): A Systematic Review and Meta-Analysis (2018) (0)
- The hepatocellular carcinoma modified Gustave Roussy Immune score (HCC‐GRIm score) as a novel prognostic score for patients treated with atezolizumab and bevacizumab: A multicenter retrospective analysis (2022) (0)
- Noninvasive tests predict liver-related events and mortality in patients with non-alcoholic fatty liver disease: sub-analysis of the CLIONE-Asia study. (2023) (0)
- The best predictive model for post-SVR HCC: can it be universal? (2022) (0)
- The GALAD Score as Potential Screening Test for Hepatocellular Carcinoma in Nonalcoholic Steatohepatitis: An International Multicenter Study (2019) (0)
- C-Reactive Protein to Albumin Ratio Predicts Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Analysis (2021) (0)
- P0786 : 100% SVR12 with ledipasvir/sofosbuvir±ribavirin for 12 weeks in Japanese patients with chronic genotype 1 hepatitis C virus who previously failed therapy with protease inhibitor + pegylated interferonα + ribavirin (2015) (0)
- Editorial: the emergence of non‐hypervascular hypointense nodules in Gd‐EOB‐DTPA‐enhanced MRI in patients with chronic hepatitis C. Authors' reply (2020) (0)
- Association of mutations in two PKR binding domains of hepatitis C virus genotype 3A and viral loads (2003) (0)
- Simple Scoring System for Predicting TACE Unsuitable among Intermediate-Stage Hepatocellular Carcinoma Patients in the Multiple Systemic Treatment Era (2021) (0)
- Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab (2022) (0)
- Identification of the suitable candidates for EOB-MRI with the high risk of the presence of non-hypervascular hypointense nodules in patients with HCV infection (2022) (0)
- Improved treatment response and bone density in patients with chronic hepatitis B (CHB) switched to tenofovir alafenamide (TAF) from other nucleos (t)ide analogue: 96-week results from a prospective multinational study (2022) (0)
- Development and Multicenter External Validation of FIB-6; A Novel, Machine-Learning, Simple Bedside Score to Rule Out Severe Liver Fibrosis and Cirrhosis in Patients with Chronic Hepatitis C (2021) (0)
- AFP is elevated more than 10 years before hepatocellular carcinoma development is detected: this observation leads to a practical risk stratification strategy (2020) (0)
- Fully automated rapid quantification of Hepatitis C Virus RNA in human plasma and serum by integrated on-chip RT-qPCR and capillary electrophoresis (2020) (0)
- Erratum: Infection with TT virus, a novel transfusion-transmissible DNA virus, in haemophiliacs and in blood products (British Journal of Hematology (1999) 105 (1114-1119)) (1999) (0)
- Association of Serum Albumin Levels and Long-Term Prognosis in Patients with Biopsy-Confirmed Nonalcoholic Fatty Liver Disease (2023) (0)
- [600] EFFICACY OF RIBAVIRIN PLUS INTERFERON-ALFA IN ELDERLY PATIENTS WITH CHRONIC HEPATITIS C (2007) (0)
- A continuous-time hidden Markov model for cancer surveillance using serum biomarkers with application to hepatocellular carcinoma (2019) (0)
- Clinical Features and Outcomes Based on Liver Injury Patterns in Liver Injury Caused by Immune Checkpoint Inhibitors (2021) (0)
- 497 – Hcv Cure by Ifn-Free Direct Acting Antivirals (DAAS) are Associated with Increased Survival in Patients with Hcvrelated Hcc: A Real-World, Propensity Score-Matched Cohort Study from the U.S. and Japan (2019) (0)
- Measurement of attenuation coefficient using ultrasound-guided attenuation parameter for evaluation of fatty liver (2018) (0)
- Relationship of atezolizumab plus bevacizumab treatment with muscle volume loss in unresectable hepatocellular carcinoma patients– multicenter analysis (2022) (0)
- Fibrosis-3 index: A new score to predict liver fibrosis in patients with Nonalcoholic Fatty Liver Disease without age as a factor (2022) (0)
- US–Japan Comparison of Hepatocellular Carcinoma Detected Under Surveillance (2020) (0)
- Response to ‘WFA+‐M2BP: a novel biomarker with diagnostic and therapeutic implications in liver diseases’ (2016) (0)
- [Hepatitis B virus infection and its prevention]. (2015) (0)
- [Clinical study of retreatment of chronic hepatitis C with interferon (IFN) for non-complete responders on initial treatment]. (1994) (0)
- Identification of Advanced Fibrosis in Hepatitis C Patients following Sustained Virologic Response: A New Predictive Model (2016) (0)
- Extended treatment duration overcomes the requirement for profound week-4 interferon responsiveness in order for hepatitis C genotype 1 patients with unfavorable IL-28B genotype to achieve sustained virologic response. (2013) (0)
- [Impact of HIV on HCV, GBV-C/HGV, and HBV infection]. (2002) (0)
- Clinical utility of COBAS AmpliPre/COBAS TaqMan HCV test for evaluating the efficacy of peginterferon plus ribavirin therapy (2008) (0)
- Survival After Intra-Arterial Treatment for Hepatocellular Carcinoma: Impact of Liver Dysfunction and Development of a Predictive Statistical Model: an International Collaborative Project (2015) (0)
- Serum biomarker (‘GALAD’) response after resection of hepatocellular carcinoma: impact of tumour recurrence (2017) (0)
- Editorial: is there a ‘precursor’ HCC lesion and can it be detected by hepatobiliary contrast‐enhanced magnetic resonance imaging? Authors' reply (2021) (0)
- Utility of Ultrasound-Guided Attenuation Parameter for the Quantification of Steatosis with Reference to MRI-Based Proton Density Fat Fraction: A Multicenter, Prospective Study (2021) (0)
- Tu1648 PROGNOSTIC IMPACT OF TYROSINE KINASE INHIBITOR SEQUENTIAL TREATMENT INCLUDING LENVATINIB FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA (2020) (0)
- P0331 : The ‘GALAD score’ for serological detection of hepatocellular carcinoma: International validation and assessment of the influence of tumour size and aetiology on model utility (2015) (0)
- Wa Monoclonal Rheumatoid Factors and Non-hodgkin Lymphoma (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Hidenori Toyoda?
Hidenori Toyoda is affiliated with the following schools:
